Health Technology Clinical Committee  
Date: November 16, 2012  
Time: 8:00 am – 5:00 pm  
Location: SeaTac Airport Conference Center  
Adopted: March 16, 2012

Meeting materials and transcript are available on the HTA website at:  
www.hta.hca.wa.gov/past_materials.html

HTCC MINUTES

Members Present: C. Craig Blackmore MD, MPH; Marie-Annette Brown PhD, RN; Joann Elmore, MD MPH; David McCulloch, MD; Carson E. Odegard DC, MPH; Richard C. Phillips MD, MS, MPH; Seth Schwartz MD, MPH; Michelle Simon PhD, ND; Michael Souter MB, Ch-B, DA, Christopher Standaert, MD; Kevin Walsh MD

Members Absent: None

HTCC FORMAL ACTION

1. Call to Order: Dr. Blackmore, Chair, called the meeting to order. Sufficient members were present to constitute a quorum.

2. September 21, Meeting Minutes: Chair referred members to the draft minutes; motion to approve and second, and adopted by the committee.

   Action: Eleven committee members approved the September 21, 2012 meeting minutes.

3. Intensity Modulated Radiation Therapy Draft Findings & Decision: Chair referred members to the draft findings and decision and called for further discussion or objection. The Intensity Modulated Radiation Therapy Draft Findings & Decision was approved and adopted by the committee.

   Action: Eleven committee members approved the Intensity Modulated Radiation Therapy Draft Findings & Decision document.

4. Stereotactic Radiation Surgery and Stereotactic Body Radiation Therapy

   Scheduled and Open Public Comments: The Chair called for public comments.

   Scheduled Public Comments: Four individuals scheduled time for public comments.

   o John Rieke, MD, American Society of Radiation Oncology
Presenting for Shilpen Patel, MD, University of Washington School of Medicine, Department of Radiation Oncology.

Presentation materials and conflict of interest forms are available with November 16 meeting materials.

No open public comments were presented.

Agency Utilization and Outcomes:

Kerilyn Nobuhara MD, MHA, Senior Medical Consultant, Health Care Authority, presented the state agency utilization rates for Stereotactic Radiation Surgery and Stereotactic Body Radiation Therapy to the committee. The full presentation is published with November 16 meeting materials.

Vendor Report and HTCC Q & A:

The Chair introduced the clinical expert, Martin Fuss, MD, professor and Vice Chair, Director Program in Image-guided Radiation Therapy, Department of Radiation Medicine, Oregon Health & Science University.

Martha Gerrity, MD, MPH, PhD, of the Center for Evidence-based Policy, Oregon Health & Science University, presented the evidence review addressing Stereotactic Radiation Surgery and Stereotactic Body Radiation Therapy. The full presentation is published with November 16 meeting materials.

Committee Discussion and Decision

The HTCC reviewed and considered the Stereotactic Radiation Surgery and Stereotactic Body Radiation Therapy technology assessment report and information provided by the state agencies. They also heard comments from the evidence reviewer, the clinical expert, the public, and agency medical directors. The committee considered all the evidence and gave greatest weight to the evidence it determined, based on objective factors, to be the most valid and reliable.

<table>
<thead>
<tr>
<th>HTCC Committee Coverage Determination Vote</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Not Covered</strong></td>
</tr>
<tr>
<td><strong>Covered Unconditionally</strong></td>
</tr>
<tr>
<td><strong>Covered Under Certain Conditions</strong></td>
</tr>
<tr>
<td>-------------------------------------------</td>
</tr>
<tr>
<td>Stereotactic Radiation Surgery</td>
</tr>
<tr>
<td>0</td>
</tr>
<tr>
<td>0</td>
</tr>
<tr>
<td>11</td>
</tr>
<tr>
<td>Stereotactic Body Radiation Therapy</td>
</tr>
<tr>
<td>0</td>
</tr>
<tr>
<td>0</td>
</tr>
<tr>
<td>11</td>
</tr>
</tbody>
</table>
• **Discussion:** The Chair called for discussion of conditions of coverage for Stereotactic Radiation Surgery and Stereotactic Body Radiation Therapy following the majority voting for coverage under certain conditions. The following conditions were discussed and approved by a majority of the clinical committee:

• **Limitations of Coverage:**
  
  • Stereotactic Radiation Surgery covered for tumors with conditions:
    ▪ Functional status- Karnofsky score greater than or equal to 50, and
    ▪ Multidisciplinary team analysis, including surgical input
  
  • Stereotactic Body Radiation Therapy (SBRT) is a covered with conditions:
    ▪ Cancers of spine/paraspinal structures, or
    ▪ non-small cell lung cancer, stage 1 inoperable, and
    ▪ Multidisciplinary team analysis, including surgical input.
    
    All other indications: Not covered

The committee checked for availability of a Medicare decision. There is no national coverage determination (NCD) for Stereotactic Radiation Surgery or Stereotactic Body Radiation Therapy.

Chair directed HTA staff to a prepare draft coverage determination document for the topic.

5. **Vitamin D Screening and Testing:**

**Scheduled and Open Public Comments:** The Chair called for public comments.

Two individuals scheduled time for public comments:
  
  o Eugene F. May, MD, NW Alliance of Multiple Sclerosis Centers
  o Nesanet Mitku, MD, NW Alliance of Multiple Sclerosis Centers

Presentation materials and conflict of interest forms are available with [November 16 meeting materials](#).

No open public comments were presented.

**Agency Utilization and Outcomes:**

G. Steven Hammond MD, MHA, PhD, Chief Medical Officer, Department of Corrections, presented the state agency utilization rates for Vitamin D Screening and Testing to the committee. The full presentation is published with [November 16 meeting materials](#).

**Vendor Report and HTCC Q & A:**

The Chair introduced the clinical expert, Susan Ott, MD, University of Washington Adjunct Professor, Department of Medicine; Radiology, Pathology and Orthopedics.
Theresa Rogstad, MPH, Senior Medical Research Analyst for Hayes, Inc., presented the evidence review addressing Vitamin D Screening and Testing. The full presentation is published with November 16 meeting materials.

Committee Discussion and Decision

The HTCC reviewed and considered the Vitamin D Screening and Testing technology assessment report and information provided by the state agencies. They also heard comments from the evidence reviewer, the clinical expert, the public, and agency medical directors. The committee considered all the evidence and gave greatest weight to the evidence it determined, based on objective factors, to be the most valid and reliable.

### HTCC Committee Coverage Determination Vote

<table>
<thead>
<tr>
<th></th>
<th>Not Covered</th>
<th>Covered Unconditionally</th>
<th>Covered Under Certain Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin D Screening and Testing</td>
<td>0</td>
<td>0</td>
<td>11</td>
</tr>
</tbody>
</table>

- **Discussion**: The Chair called for discussion of conditions of coverage for Vitamin D Screening and Testing following the majority voting for coverage under certain conditions. The following conditions were discussed and approved by a majority of the clinical committee:

- **Limitations of Coverage**:
  - Not covered as a part of **routine screening**
  - **Testing** is covered in individuals with:
    - A disease or condition known to cause, or be caused by, Vitamin D abnormality; or
    - Radiologic or laboratory findings that are positive for markers of Vitamin D abnormality.

The committee checked for availability of a Medicare decision. The Centers for Medicare and Medicaid Services have no published national coverage determinations (NCD) for Vitamin D testing and screening.

Chair directed HTA staff to prepare draft coverage determination document for the topic.

6. The Chair called for further comments. No further comments on review of Vitamin D Testing and Screening.
7. Review of draft key questions open for public comment: Cochlear Implants: Bi- versus Unilateral. HTA staff reminded committee members of the open comment period for key questions; committee reviewed draft key questions.

8. Meeting adjourned.